Reuters logo
BRIEF-AstraZeneca's durvalumab average monthly cost around $15,000
May 1, 2017 / 7:16 PM / 7 months ago

BRIEF-AstraZeneca's durvalumab average monthly cost around $15,000

May 1 (Reuters) - AstraZeneca

* Says average wholesale acquisition cost of durvalumab around $15,000/month, following FDA approval of drug for bladder cancer Further company coverage: (Reporting by UK bureau)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below